Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Current Breast Cancer Reports
Metadata
Title
Role of Breast MRI in Patients with Newly Diagnosed Breast Cancer
Publication date
01-06-2016
Published in
Current Breast Cancer Reports / Issue 2/2016
Print ISSN: 1943-4588
Electronic ISSN: 1943-4596
DOI
https://doi.org/10.1007/s12609-016-0205-8

Other articles of this Issue 2/2016

Current Breast Cancer Reports 2/2016 Go to the issue

Biomarkers (S Dawood, Section Editor)

Comprehensive Gene Mutation Profiling of Breast Tumors: Is It Ready for Prime Time Use?

Local-Regional Evaluation and Therapy (EP Mamounas, Section Editor)

New Developments in Assessing Risk of Local Recurrence in Patients with Ductal Carcinoma In Situ after Lumpectomy and Breast Radiation

Local-Regional Evaluation and Therapy (EP Mamounas, Section Editor)

Nipple-Sparing Mastectomy in Patients with Germline BRCA Mutations: Is it Safe?

Local-Regional Evaluation and Therapy (EP Mamounas, Section Editor)

Regional Nodal Radiotherapy in Early-Stage Breast Cancer: Where Are We in 2016?

Biomarkers (S Dawood, Section Editor)

Defining the Prognostic and Predictive Role of PIK3CA Mutations: Sifting Through the Conflicting Data

Local-Regional Evaluation and Therapy (EP Mamounas, Section Editor)

Oncoplastic Breast Surgery: What, When and for Whom?
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits